VUEWAY® injection is a highly kinetically stable, macrocyclic GBCA with the highest values of longitudinal relaxivity (r1) among macrocyclic GBCAs approved in major global markets.1 In clinical studies, VUEWAY® injection has demonstrated effective contrast enhancement at a dose of 0.05 mmol/kg—half of the 0.1 mmol/kg dose used with other GBCAs—resulting in reduced gadolinium exposure for patients.2,3,4 This approach aligns with clinical guidance from radiology societies, which emphasizes the use of the lowest effective GBCA dose when contrast-enhanced imaging is required.4
“Reducing gadolinium exposure is not only a clinical priority but increasingly an environmental one,” said Dr. Kate Hanneman, Radiologist & Deputy Lead for Sustainability at the Joint Department of Medical Imaging, University of Toronto. “High-relaxivity gadolinium-based contrast agents that deliver diagnostic confidence at half the standard dose represent an important advance for Canadian patients, supporting both patient safety and environmental stewardship.”